Welch & Forbes’s BioMarin Pharmaceuticals BMRN Stock Holding History

Welch & Forbes’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,040	Closed	-$214K	–	344
2015 Q4	$214K	Buy	+2,040	New	+$213K	0.01%	306
2015 Q3	–	Sell	-1,840	Closed	-$252K	–	328
2015 Q2	$252K	Hold	1,840	–	–	0.01%	306
2015 Q1	$229K	Buy	+1,840	New	+$195K	0.01%	311

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Welch & Forbes's BMRN Position: Q1 2016 in Review

Welch & Forbes sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 2,040 shares — an estimated $214K sold.

Welch & Forbes first reported a position in BMRN in Q1 2015 and held it in 3 quarters. The position peaked at $252K in Q2 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Welch & Forbes reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Welch & Forbes sold 2,040 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $214K.
Welch & Forbes first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 3 quarters.
Welch & Forbes's BioMarin Pharmaceuticals position peaked at $252K in Q2 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Welch & Forbes's 13F filing for Q1 2016, filed 5 May 2016.